Spun out in 2007 by Oxford University Innovation, the company has commercialised technological breakthroughs in a new generation of biomarkers for cancer and other diseases.
Read more (Sir William Dunn School of Pathology website)
Biomarker spinout founded by Dunn School alumni holds successful flotation on AIM
Clinical Trials Innovation Research
6 December 2016
Oxford Biodynamics, a biomarker company set up by former Dunn School researchers Dr Alexandre Akoulitchev and Dr Aroul Ramadass, completed a successful flotation on AIM, the London Stock Exchange’s international market for smaller growing companies, on 6 December 2016.